创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels Biotechnology: Characterization and application of SCID mouse NK efficacy models

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-05-20 15:18
  • Views:

(Summary description)In the biomedical field, accurate and efficient experimental models are crucial for drug development and evaluation. The SCID mouse NK efficacy model from InnoModels Biotechnology is one of such industry-leading innovations, whose unique design and high degree of simulation have opened up new avenues for immunotherapy research. In the following, we will discuss in detail the characteristics of this model and its application in drug discovery and development.

InnoModels Biotechnology: Characterization and application of SCID mouse NK efficacy models

(Summary description)In the biomedical field, accurate and efficient experimental models are crucial for drug development and evaluation. The SCID mouse NK efficacy model from InnoModels Biotechnology is one of such industry-leading innovations, whose unique design and high degree of simulation have opened up new avenues for immunotherapy research. In the following, we will discuss in detail the characteristics of this model and its application in drug discovery and development.

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-05-20 15:18
  • Views:
Information

In the biomedical field, accurate and efficient experimental models are crucial for drug development and evaluation. The SCID mouse NK efficacy model from InnoModels Biotechnology is one of such industry-leading innovations, whose unique design and high degree of simulation have opened up new avenues for immunotherapy research. In the following, we will discuss in detail the characteristics of this model and its application in drug discovery and development.
SCID, or Severe Complex Immunodeficiency, is a rare genetic disorder in which the patient's immune system fails to function properly. InnoModels' SCID mouse model perfectly mimics this disease, allowing researchers to study the function of the immune system and the mechanisms of the disease in greater depth. On this basis, researchers further introduced NK cells (natural killer cells) into the model and created the SCID mouse NK pharmacodynamic model, making the model more targeted and specialized.
First of all, the SCID mouse NK efficacy model is highly simulative. This model utilizes the growth of human-derived tumor cell lines in SCID mice to provide a model for drug testing that is close to the human environment. The ability of the human tumor cell line to grow normally in SCID mice and the presence of NK cells allows this model to mimic the true response of the human immune system. This allows researchers to more accurately predict the effects and side effects of drugs in the human body, greatly improving the efficiency and success rate of drug development.

 


Secondly, the SCID mouse NK efficacy model is professionally targeted. This model is specifically designed for tumor immunity drugs that target NK cells, which play an important role in the immune system by recognizing and attacking abnormal cells, including tumor cells, to ensure the relevance and accuracy of the test. Therefore, immune drugs targeting NK cells have great potential in tumor therapy.The SCID mouse NK efficacy model can directly assess the effects of these drugs on NK cells, thus providing strong support for drug development.
In addition, the SCID mouse NK efficacy model also has the ability of comprehensive evaluation. By combining SCID mouse NK cells and human tumor cell lines, this model can comprehensively assess the immunomodulatory effect and anti-tumor activity of drugs. This can not only help researchers understand the mechanism of drug action in the immune system, but also assess the efficacy and safety of drugs, providing an important basis for further optimization of drugs.
Finally, the SCID mouse NK efficacy model is widely used in drug development. It can be used not only to evaluate the efficacy and safety of novel immunotherapies, but also to study the function of the immune system, the mechanism of disease occurrence and the interaction between drugs and the immune system. In addition, the model can be used to optimize drug dosages and treatment regimens, improve therapeutic efficacy and reduce side effects.
In summary, the SCID mouse NK efficacy model of InnoModels Biotechnology has shown great potential in the biomedical field with its unique features and wide application value. It can not only provide researchers with an experimental platform close to the human environment, but also help them gain a deeper understanding of the function of the immune system and the mechanism of disease occurrence. In the future, with the continuous improvement and optimization of the model, it is believed that it will bring more breakthroughs and innovations for drug development and evaluation.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司